Biocraft/E. Merck agreement
Biocraft announced on July 1 that last April it entered into an agreement with the West German company's subsidiary Arcana Chem. Pharm. for joint development and licensing of sustained release pharmaceutical preparations. Biocraft said FDA approval wiil initially be sought for four unspecified products, some of which are already marketed in Germany, Austria and other European countries
You may also be interested in...
The final opinion of ECHA’s Socio-Economic Analysis Committee, published on 1 March, is largely unchanged from its July 2020 draft opinion with regard to microplastic in cosmetic products. That means industry may have to convince EU member state authorities that the restriction proposal has a serious proportionality problem.
Representatives from cardiac monitoring device manufacturers and professional societies are working together to persuade Medicare carrier Novitas to reconsider its payment rates for extended cardiac monitoring. See what Michael Coyle, iRhythm’s CEO, said about it here.
As agency implements testing contract for its staff, sponsors are drawing up protocols to ensure inspector safety and forwarding them to FDA, but still can’t trigger an inspection.